Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nippon Chemiphar Co. Ltd.

Latest From Nippon Chemiphar Co. Ltd.

Nippon Chemiphar Sees Profits Halved

Japanese NHI drug price revisions implemented in October 2019 are responsible for operating profits halving amid declining sales and future uncertainty, Nippon Chemiphar said as it slashed its full-year forecast.

Sales & Earnings Japan

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Asia On The Move: Personnel News From Key Players In The Region

Takeda, AstraZeneca appoint new VPs, Mindray ditches its co-CEO system for a sole CEO, and Teva has a new head for Asia-Pacific. High-level personnel changes have also taken place at Eisai, Merck and other pharma companies in Asia.

BioPharmaceutical Medical Device

Daiichi Sankyo enters Japan's generics sector

Daiichi Sankyo, Japan's second-largest research-based pharmaceutical firm, has entered the growing domestic generics sector with the start of commercial operations at its new Daiichi Sankyo Espha subsidiary on 1 October.

See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Laboratory Testing Services
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Pharmaceuticals
    • Generic Drugs
  • Services
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Nippon Chemiphar Co. Ltd.
  • Senior Management
  • Kazushiro Yamaguchi, Pres. & CEO
  • Contact Info
  • Nippon Chemiphar Co. Ltd.
    Phone: (81) 3-3863-1211
    2-2-3, Iwamoto-cho
    Tokyo, 101-0032